Natalie S. Callander

Statistics

Publications

148

Citations

14.8K

H-Index

Active since

1992

Affiliations

University of Wisconsin Carbone Cancer Center(Current)

University of Wisconsin–Madison

Medical College of Wisconsin

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Natalie S. Callander is an author at University of Wisconsin Carbone Cancer Center specializing in medicine, multiple myeloma, and multiple myeloma therapy.

ORCID

Publications per year

1992–2025

148

Publications

148

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister et al. · New England Journal of Medicine · 2012 · 1.1K citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander et al. · The Lancet Oncology · 2009 · 933 citations · Full text

Medicine, Hematology, Oncology +11

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

Medicine, Oncology, Pharmacotherapy +14

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 705 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 148